July 31, 2026

Company Name	Otsuka Holdings Co., Ltd.
Name of Representative	Makoto Inoue President and Representative Director, CEO
Code Number	4578, Prime market of the Tokyo Stock Exchange
Contact	Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411)

Notice Regarding Revision of Full-Year Consolidated Financial Forecast and Payment of Interim Dividend and Revision of Year-End Dividend Forecast (Increase in Dividend)

Otsuka Holdings Co., Ltd. (the "Company") hereby announces that, at the meeting of the Board of Directors held on July 31, 2026, it resolved to revise the consolidated financial forecast for the fiscal year ending December 31, 2026 (January 1, 2026 to December 31, 2026), previously announced on February 13, 2026, and to approve the payment of an interim dividend with a record date of June 30, 2026, as well as the revision of the year-end dividend forecast, as described below.

1. Revision of Full-Year Consolidated Financial Forecast

(1) Revision of Consolidated Financial Forecast for FY2026 (January 1, 2026 to December 31, 2026)

	Revenue	Business profit	Operating profit	Profit before tax	Profit for the period	Profit attributable to owners of the Company	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	2,520,000	355,000	360,000	353,000	269,000	265,000	504.94
Revised forecast (B)	2,725,000	470,000	469,000	472,000	360,000	355,000	675.47
Amount of change (B-A)	205,000	115,000	109,000	119,000	91,000	90,000	
Change (%)	8.1%	32.4%	30.3%	33.7%	33.8%	34.0%	
(Reference) FY2025 Actual	2,468,892	446,129	479,375	468,037	366,216	363,150	685.06

(2) Reasons for the revision

Based on the results for the first half of FY2026, the Company has revised upward the consolidated financial forecast announced on February 13, 2026.

In the Pharmaceutical Business, the key growth drivers of the Fourth Medium-Term Management Plan, including the antipsychotic drug REXULTI, the antineoplastic agent LONSURF, and the anti-APRIL antibody VOYXACT, have continued to progress steadily. In addition, due to the later-than-anticipated entry of generic versions of JYNARQUE in the United States and ABILIFY MAINTENA in Europe, revenue in the Pharmaceutical Business is now expected to reach JPY 1,934.0 billion, exceeding the forecast announced in February 2026 by JPY 195.0 billion.

In the Nutraceutical Business, the For Healthier Life category has continued to perform well, supporting solid business performance. The Company has also revised its foreign exchange assumptions to reflect the depreciation of the Japanese yen against the U.S. dollar and the euro (USD: ¥150 to ¥158; EUR: ¥175 to ¥185). As a result, revenue, business profit, operating profit, profit for the period, and profit attributable to owners of the Company are expected to exceed the previous forecast.

2. Interim Dividend

(1) Details of Interim Dividend

	Decided Amount	Most Recent Forecast (Announced on February 13, 2026)	Previous Fiscal Year (Interim FY2025)
Record date	June 30, 2026	June 30, 2026	June 30, 2025
Dividend per share	JPY 100.00	JPY 70.00	JPY 70.00
Total dividend amount	JPY 52,539 million	-	JPY 36,969 million
Effective date	September 1, 2026	-	September 1, 2025
Source of funds	Retained earnings	-	Retained earnings

(2) Reason

Based on the favorable results for the second quarter of FY2026 and the upward revision of the consolidated financial forecast for the fiscal year ending December 31, 2026 announced today, the Company has revised the interim dividend from the previously forecast ¥ 70.00 per share to ¥ 100.00 per share.

3. Revision of Annual Dividend Forecast

(1) Details of Revision

	Annual dividend per share (JPY)		
	Interim	Year-end	Total
Previous forecast (Announced on February 13, 2026)	JPY 70.00	JPY 70.00	JPY 140.00
Revised forecast	-	JPY 100.00	JPY 200.00
Results for FY2026	JPY 100.00	-	-
Results for FY2025	JPY 70.00	JPY 70.00	JPY 140.00

(2) Reason

In line with its progressive dividend policy, the Company has revised the year-end dividend forecast from the previously forecast JPY 70.00 per share to JPY 100.00 per share, the same amount as the interim dividend.

As a result, the Company plans to pay an annual dividend of JPY 200.00 per share (consisting of an interim dividend of JPY 100.00 and a year-end dividend of JPY 100.00), representing an increase of JPY 60.00 per share from the previous forecast.

4. Policy of dividend

The Company has adopted a stable dividend policy, intending to increase or maintain the annual dividend per share, and aims to enhance shareholder returns.

Note: The above forecasts are based on information available and assumptions deemed reasonable by the Company at the time of this announcement. Actual operating results may differ from these projections due to various factors.